Showing 3881-3890 of 4165 results for "".
- GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of Lumevoq Vector DNA in Contralateral Eyes After Unilateral Injectionhttps://modernod.com/news/gensight-biologics-announces-publication-of-non-human-primate-study-reporting-presence-of-lumevoq-vector-dna-in-contralateral-eyes-after-unilateral-injection/2480491/GenSight Biologics announced that the journal "Molecular Therapy – Methods and Clinical Development" has published the results of a mechanistic study demonstrating the transfer of Lumevoq vector DNA from the injected eyes to the non-injected eyes of non-human prim
- jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapyhttps://modernod.com/news/jcyte-identifies-key-anatomical-biomarker-predictive-of-substantial-restoration-of-visual-function-in-retinitis-pigmentosa-patients-treated-with-jcell-therapy/2480452/jCyte announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its phase 2b study, the largest randomized clinical trial ever con
- Kala Pharmaceuticals Acquires Combangio, Maker of Regenerative Biotherapies for Severe Ocular Surface Diseaseshttps://modernod.com/news/kala-pharmaceuticals-acquires-combangio-maker-of-regenerative-biotherapies-for-severe-ocular-surface-diseases/2480449/Kala Pharmaceuticals announced that it has acquired Combangio, a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex w
- Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-publication-in-ophthalmology-of-onset-2-phase-3-data-on-tyrvaya-varenicline-solution-nasal-spray/2480446/Oyster Point Pharma announced that results from the multicenter, randomized, double-masked, vehicle-controlled phase 3 clinical trial (The ONSET-2 study) of Tyrvaya Nasal Spray (varenicline solution) have been published in Ophthalmology.1 
- Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meetinghttps://modernod.com/news/nicoxs-ncx-470-dolomites-phase-2-results-in-glaucoma-patients-to-be-presented-at-the-aao-2021-annual-meeting/2480425/Nicox SA announced a poster presentation highlighting responder analyses results from the Dolomites phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension at the American Academy of Ophthalmology 2021 Annual Meeting being held from N
- CooperVision Presents Presbyopia Research, Introduces MyDay Daily Disposable Multifocal at Academy 2021https://modernod.com/news/coopervision-presents-presbyopia-research-introduces-myday-daily-disposable-multifocal-at-academy-2021/2480390/As part of the American Academy of Optometry 2021 virtual press conference, CooperVision presented results of research into the daily complexity of dealing with presbyopia and how this may affect clinical choices. The work was conducted in support of the launch of CooperVision’s new MyDay&n
- Aurion Biotech Names Members of Medical Advisory Boardhttps://modernod.com/news/aurion-biotech-names-members-of-medical-advisory-board/2480358/Aurion Biotech announced the company’s medical advisory board, composed of the world’s most eminent ophthalmologists. The board will collaborate with the company’s executive team in clinical development, and is chaired by Edward Holland, MD, who was recently
- Ophthalmos Institute Reports Positive Efficacy Data of Eyetas' Omega 3 Fatty Acids Supplementation on Dry AMD and Stargardt Diseasehttps://modernod.com/news/ophthalmos-institute-reports-positive-efficacy-data-of-eyetas-omega-3-fatty-acids-supplementation-on-dry-amd-and-stargardt-disease/2480325/Ophthalmos Research and Educational Institute (OREI) announced positive clinical and statistically significant topline results from a small randomized, double-blind multicenter study in Europe assessing the potential effects of omega 3 fatty acids supplementation (Eyetas) in modera
- Nidek Launches Retina Scan Duo 2 OCT/Fundus Camerahttps://modernod.com/news/nidek-launches-retina-scan-duotm-2-octfundus-camera/2480323/Nidek has announced the launch of the Retina Scan Duo 2, a combined OCT and fundus camera system. The Retina Scan Duo 2 incorporates new features designed to enhance screening and clinical efficiency, in addition to user-friendly features that were incorporated from the previous model.<
- Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patientshttps://modernod.com/news/adverum-data-shows-gene-therapy-maintained-efficacy-durability-safety-in-wet-amd-patients/2480318/Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data f